DMD #40188

Introduction
Eltrombopag, a non-peptide thrombopoietin receptor agonist, has recently been approved for treatment of idiopathic thrombocytopenic purpura (ITP) (Bussel et al., 2007) . It is a biphenyl hydrazone with its full chemical name as follows: 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxy-3-biphenylcarboxylic acid. The pharmacokinetics, metabolism and excretion of eltrombopag were studied in healthy humans following oral administration of Mammalian intestines contain more than 500 different species of bacteria with up to 10 11 bacterial cells/g of luminal contents (Guarner and Malagelada 2003) . Gut microbes contribute to diverse mammalian physiological functions, including host defense against pathogens in the gut, contribution to immunity through generation of signal molecules/metabolites, development of intestinal wall structure, fermentation of nondigestible dietary fibers, and energy recycling by anaerobic metabolism of peptides and proteins (Nicholson et al, 2005) . These intestinal bacteria perform a variety of metabolic reactions including hydrolysis, acetylation, reduction and decarboxylation (Ilett et al 1990; Sweeny et al, 2010) . Many drugs are identified as substrates of intestinal microbial metabolism (Sousa et al 2008) .
In this report, we described results from our investigations of gut microbial involvement in eltrombopag degradation. The potential for interaction of eltrombopag with antibiotics was also investigated in mice.
DMD #40188
0.5% bacteriological peptone in 0.1 M sodium phosphate buffer (pH 7.4). The tube was then sealed with Teflon tape, removed from the glove chamber and incubated at 37ºC for 1 h. Following the pre-incubation, the cecal content suspension was returned to the glove chamber for preparation of drug incubations.
A stock solution of [ removed from the glove bag and incubated at 37ºC for 24 h. Reactions were stopped by adding 2 mL of a freshly prepared mixture of acetonitrile :ethanol (80:20, v:v) . Samples were then centrifuged at approximately 3,500 g av at 4°C for 5 minutes. The resulting supernatant was analyzed by radio-HPLC and LC/MS. Control incubations without eltrombopag (no-drug control) were conducted in parallel using blank incubation media containing an appropriate amount of DMSO in place of the eltrombopag test solution without the test substance. Control incubations without cecal content suspension (no-cell control) were also conducted using the incubation media and test solution only.
Incubations with cecal contents harvested from five male CD1 mice (approximately 58 g each, Charles River Laboratories, Inc., Raleigh, NC) were conducted under identical conditions as described above, except that 10 mL of incubation media was used to initially collect the cecal contents.
Incubation with human fecal contents -A fresh fecal sample was collected from an anonymous donor at GlaxoSmithKline, Upper Merion, PA. To minimize atmospheric contact, the sample was immediately submerged in nitrogen-gassed 0.1 M sodium phosphate buffer (pH 7.4) upon collection, and homogenized under a stream of nitrogen gas. After homogenization, the fecal sample was transferred to the nitrogen-filled glove chamber where 10 mL of the homogenate was mixed into 20 mL of the initial incubation media. Identical incubations as described above were conducted with the fecal homogenate.
Gut microbial viability assay -Gut anaerobic microbial activity was examined by mixing 1 mL of each cecal/fecal content suspension with 1 mL of methylene blue (50 μ g/mL) in incubation media at 37ºC for 24 h (LeBoffe and Pierce, 1996) . Samples with viable microbial colonies remained colorless throughout the incubation (reduced methylene blue is colorless).
In vitro antibiotic treatment -To confirm the involvement of gut microbes in the cleavage of eltrombopag in vitro, antibiotics were added to the incubations with rat cecal contents. Cecal suspensions were pre-treated for 24 h with a mixture of bacitracin, neomycin and streptomycin in saline at approximately 10 mg/mL each (modified from DMD #40188 Kinouchi et al, 1993) . Another dose of antibiotics was added to the suspensions 4 h prior to sample incubation. No-cell controls were prepared with and without antibiotics.
Microbial viability before and after antibiotic treatment was confirmed by methylene blue assay as described above.
Aerobic in vitro incubations -An aliquot of the rat cecal content suspension was gently aerated with 95% O 2 /5% CO 2 during the 1 h pre-incubation. Identical incubations as described above were conducted with this aerated cecal content suspension, except that incubations were performed under a 95% O 2 /5% CO 2 atmosphere.
Excretion and Pharmacokinetics of Eltrombopag in Mice Pretreated with
Antibiotics.
Urinary excretion -An excretion study was conducted with [ were divided into four groups as described in Urine samples were pooled per group upon collection and centrifuged at 15800 g av at ambient temperature for 5 minutes to remove any particulates. Radioactivity present in the pooled urine samples was measured by liquid scintillation counting prior to and after centrifugation to ensure that no radioactivity had associated with the particulates.
Metabolite profiles in the urine were determined by radio-HPLC and LC/MS. contents from the mice of 24 h sample collection were collected and incubated with methylene blue as described above to determine gut microbial activity. following four step gradient was used: 0 to 30 min, 10% solvent B in solvent A; 30 to 60 min, 10% to 30% B in A; 60 to 90 min, 30% to 100% B in A; 90 to 100 min, 100% B.
Pharmacokinetics
The gradient was then returned to 10% B in A and the column allowed to equilibrate at the starting conditions for 10 min before next injection. Urine and cecal/fecal content supernatants were analyzed with on-line radio-detection, during which the eluent was mixed with Ultima Flo M scintillant at a ratio of 1:3 by volume. The radioactivity data were collected at a rate of 1 point/second.
Mass Spectroscopic Analysis.
Qualitative analysis -Metabolite characterization was conducted by LC-MRM (multiple reaction monitoring ) analysis. The LC conditions were similar to those used for Quantitative analysis of eltrombopag -Plasma samples were analyzed using a validated analytical method based on protein precipitation, followed by high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC/MS/MS) analysis as eltrombopag were determined using a standard calibration curve constructed with standard solutions prepared with human plasma over the range of 10 to 2500 ng/mL.
Using a 50 μL aliquot of plasma, the lower limit of quantification for the assay was 10.0 ng/mL and the higher limit of quantification was 2500 ng/mL. Table 2 . For all three groups, the peak plasma concentrations were achieved within 1 hour post dose, and remained quantifiable for 24 hours. The systemic exposures (AUC 0-24h ) and C max of eltrombopag in the naive and saline treated mice were similar, with value ranges of 93.9-109 μg.h/mL and 21.2-21.5 μg/mL, respectively, suggesting that two daily gavages of saline over the course of 5 days had no notable impact on eltrombopag pharmacokinetics in mice. The C max value of eltrombopag in the antibiotic treated mice was also comparable (19.3 μg/mL) to the untreated group (21.5 μg/mL). The (AUC 0-24h ) in the antibiotic treated mice was slightly lower at 70.3 μg/mL. and M8, and a glucuronide of M8 (metabolite M24, exact structure unknown) were detected. SB-611855 itself was not observed in the urine following intravenous administration.
Quantitative analysis of SB-611855
Pharmacokinetics of SB-
Structural Characterization of Metabolites. A summary of HPLC retention times and
MRM transitions for metabolites are depicted in Table 3 . SB-611855 has been characterized by NMR analysis in a previous study (Deng et al, DMD/2011/040170). Thus, after gut microbial cleavage, the phenylpyrazole portion of eltrombopag likely followed a similar disposition pattern to that of the biphenyl moiety did (absorption, conjugation and renal elimination).
The rapid absorption and plasma clearance of SB-611855 observed in mice is likely the reason no circulating cleavage products have ever been detected in animal or human eltrombopag metabolism studies. In those studies, the plasma sampling for metabolic profiling was sparse (typically at 4, 12, 24, and 48 hours post dose only), and, therefore, any quantifiable cleavage products in circulation would be easily missed. As Interestingly, however, low levels of digoxin (16% of dose) were metabolized by gut microbes in humans (Greenwood et al, 1975) and notable reduction of urinary/fecal elimination of metabolites of digoxin has been observed in patients upon antibiotic treatment (erythromycin or tetracycline for 5 days) (Lindenbaum et al, 1981) , but the serum concentrations of digoxin increased by two fold in that study (Lindenbaum et al, 1981) . Digoxin disposition has been known to be complicated. In addition to gut bacterial metabolism, direct secretion of digoxin to gut lumen by p-glycoprotein has also played a role (Mayer et al, 1996) . Erythromycin is a known Pgp inhibitor (Bjornsson et al, 2003 and Eriksson et al, 2006) . Thus, the increase in serum digoxin concentrations observed by Lindenbaum et al could have resulted, at least in part, from inhibition of Pgp-mediated direct and/or biliary secretion of digoxin.
Animals, including humans, contain trillions of microbes in their gastrointestinal tract.
Humans tend to have the highest gut bacterial concentrations (Rowland 1988) , which may explain the higher amounts of eltrombopag cleavage products observed in man (20% of dose) than in rodents (< 10%) following oral administration (European Public Assessment Report, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001110/WC500089964.pdf). A single human gut could contain more than 400 bacterial species, the majority of which are anaerobic (Goldin, 1990) . Human gut microbial populations and their activities in humans have been known to differ among individuals (Smith 1965; Rowland 1986 and Scheline 1973 products varied notably between six subjects in the human radiolabel study, ranging from 23% to 45% of the dose (Deng et al, DMD/2011/040170) . It has long been recognized that gut microbes contribute to the metabolism of numerous drugs (Sousa et al, 2008) .
One of the best characterized examples was reductive deactivation of the cardiac glycoside digoxin by Eubacterium lentum, a common anaerobe in the colon (Dobkin et al, 1983) . Gut microbial cleavage of a hydrazine/hydrazone has been rare, however. Antila et al (1999) suggested that the hydrazone linkage of levosimendan was reductively cleaved by microbes in lower gastrointestinal tract in dogs, A cleavage product of levosimendan (OR-1855) was then absorbed and further metabolized to a pharmacologically active component in humans (Antila et al, 2004 ).
In conclusion, human and animal gut anaerobic bacteria readily cleaved eltrombopag. A cleavage product, SB-611855, was readily absorbed in mice, conjugated and eliminated in urine as the same urinary metabolite of orally administered eltrombopag in humans.
Antibiotic treatment sharply reduced urinary elimination of eltrombopag related material, but had no notable impact on eltrombopag plasma exposures in mice. Antibiotic coadministration unlikely leads to significant changes in eltrombopag exposures in humans.
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